The MosaiQ solution is a next-generation IVD solution for autoimmune diseases, allergies and beyond. The multiplexed, fully automated planar microarray platform enables syndromic testing for complex ...

The MosaiQ AiPlex VAS multiplex assay is designed to simultaneously detect three autoantibody markers - MPO, PR3, and GBM - using only 10 µl of patient serum. The assay runs on the MosaiQ instrument ...

AliveDx has submitted a 510(k) premarket notification seeking approval from the US Food and Drug Administration (FDA) for its MosaiQ AiPlex Connective Tissue Diseases (CTDplus) microarray. This ...

Molecular Disease Screening Microarray Feasibility Study Completed Initial Serological Disease Screening FDA 510(k) Submission Accepted Commencement of EU Expanded Immunohematology Field Trial ...

Elekta's open connectivity expansion delights customers with the widest choice of delivery and planning systems available in the market MOSAIQ-microSelectron Digital connectivity is the latest in ...

ATLANTA, Feb. 2, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that its MOSAIQ ® Oncology Information System (OIS) and Versa HD™ linear accelerator have been named "Best in KLAS" in the 2021 ...

The MosaiQ AiPlex CD is designed to improve the accuracy and speed of celiac disease diagnosis while simplifying laboratory workflows The MosaiQ AiPlex CD multiplex assay, which received IVDR-CE mark ...

Received feedback from the European notified body after review of Expanded IH submission Pleased with feedback and expect to submit a response to the questions in the next couple of weeks Continue to ...

AliveDx, the global in vitro diagnostics company that aims to transform patient care, announces that the MosaiQ AiPlex Vasculitis (VAS) assay achieved IVDR-CE Mark. This means that the MosaiQ AiPlex ...

Elekta has introduced MOSAIQ Oncology Informatics software platform at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting. MOSAIQ is a comprehensive, open EMR designed to meet the ...